P
RINCETON, NJ--Orchid Biocomputer said it has changed its name to Orchid BioSciences to reflect the company’s current and future direction in the genetic diversity and pharmacogenetics fields. "Orchid has grown in new directions that didn’t exist when the company formed in 1995," said Dale Pfost, Orchid’s chairman, president, and CEO. "We believe our new name is commensurate with the future of Orchid and the many exciting possibilities that await the company, the genetics industry, and the future of medicine and bioscience."
According to a report in Nature Biotechnology, Pfost said the company is planning an initial public offering in coming weeks to capitalize on the favorable biotech markets.